KR102368892B1 - A composition for anti-inflammatory comprising extracts of single leaf cremastra and sigesbeckia glabrescens makino - Google Patents

Abstract

The composition containing the extracts of Single-leaf cremastra and Sigesbeckia glabrescens makino of the present invention as an active ingredient has an antioxidant effect due to an excellent DPPH free radical scavenging activity, and also has an anti-inflammatory effect by suppressing the production of NO and inflammatory cytokines. In addition, the composition of the present invention has the effect of inhibiting the production of IL (interleukin)-6, IL-8, IL-1β, IL-4 and IL-13, which are cytokines expressed during inflammatory responses in human keratinocytes (HaCaT cells), inhibiting the activity of MAPKs, inhibiting the expression of TARC and MDC, which are types of chemokines produced during inflammatory reactions, and regulating the expression of NF-κB and IκBα, and has an antibacterial effect against external stimuli or pollutants, thereby preventing inflammations. The pharmaceutical composition according to the present invention has an excellent antiviral effect against Varicella zoster virus. In addition, the composition according to the present invention has an antiviral effect due to improved immunity, and in particular, has excellent antiviral effect not only in the early stage of infection with the Varicella zoster virus (at the time of chickenpox rash), but also during an incubation period and when shingles is confirmed after the incubation period. In other words, the pharmaceutical composition according to the present invention still has an excellent antiviral effect even when administered 24 hours after being infected with the Varicella zoster virus.

Description

{A composition for anti-inflammatory comprising extracts of single leaf cremastra and sigesbeckia glabrescens makino}

The present invention relates to an anti-inflammatory composition comprising an extract of yaknan and Jindeukchal, and more particularly, to a pharmaceutical composition having an anti-inflammatory effect comprising the extract of yaknan and jindeukchal as active ingredients.

Recently, with the improvement of living and income level, there is a lot of interest in improving the quality of life. In particular, interest in the development of bioactive substances for body diseases and metabolism, including antioxidants, has increased as a countermeasure for aging, various inflammatory diseases, and cancer (KB Kim, et al., Journal of Nutrition and Health. 50(5)) ;415-425 (2017)). In order to supply the necessary energy in the living body, biochemical oxidation reactions occur constantly, and reactive oxygen species (ROS), which are generated during this process, is the most stable form of oxygen, triplet oxygen, in the oxidation and reduction process. Singlet oxygen produced by superoxide anion, hydroxyl radical, free radical in an unstable state such as hydrogen peroxide and hydrogen peroxide (H2O2). Because it reacts easily with substances, if it is not removed from the body, oxidative stress is caused. Since this oxidative stress is linked to the inflammatory response, it induces lipid peroxidation in various metabolic processes and damages proteins, cell membranes, and DNA to induce cell aging and transformation, leading to stroke, cancer, arteriosclerosis, Alzheimer's disease, Parkinson's disease, etc. , atherosclerosis, etc. (Valko M, et al., Int J Biochem Cell Biol. 39:44-84 (2007); and Halliwell B, et al., NY, USA. 968 (1999)). Physiological antioxidant enzymes that remove the activated carbon thus generated to protect the living body include superoxide dismutase (SOD), catalase, glutathione-peroxidase (GSHpx) and glutathione S -Transferase (glutathione S-transferase, GST), etc., and α-tocopherol, β-carotene, ascorbic acid and glutathione are known as small molecule antioxidants or free radical scavenging agents (Kim SM, et al. ., Life Sci. 90 (21-22); 874-882 (2012)).

On the other hand, internal inflammation is a physical reaction to regenerate damaged tissue as a defense mechanism that occurs in living tissue to respond to external stimuli such as physical and chemical stimuli or tissue-damaging bacterial infection from the outside. However, the persistent inflammatory response rather increases vascular permeability by vasoactive substances such as histamine, prostaglandin, leukotriene, and hydroxyeicosatetraenoic acid, leading to chronic inflammation or promoting mucosal damage, resulting in pain and edema. , causes dysfunction such as fever, and causes the development of inflammatory diseases and cancer ([BK Kang, et al., Cells in Mice. Microbiol. Biotechnol. Lett. 43, 112-119, 2015]; [BK Kang, et al. ., Microbiol. Biotechnol. Lett. 44, 236-245, 2016]; and [MJ Kim, et al., Korean Society for Biotechnology and Bioengineering Journal. 32, 352-360, 2017]). Macrophages, one of the cells involved in the inflammatory response in the body, are cells that regulate the inflammatory response and immune function through phagocytosis and play a very important role in maintaining homeostasis ([S Woo, et al., Cells. Korean J Plant Res. 31. 466-477, 2018]; [JH Kim, et al., The Korean Society of Food Preservation. 24, 1149-1157, 2018]; [TH Lee, et al., Mol. Cells. 23 , 398-404, 2007] and [D Bishop-Bailey, et al., J. Environ. Pathol. Tox. Oncol. 21, 93-101, 2002]). Macrophages are activated by stimulation of lipopolysaccharide (LPS), an outer membrane component of Gram-negative bacteria, and play a pivotal role in the body's defense in the early stage of infection, but macrophages activated by excessive LPS stimulation are TNF-α), pro-inflammatory cytokines such as interleukin (IL)-1β and IL-6, and GM-CSF, an inflammatory chemokine, are excessively secreted to inhibit inflammation mediators such as nitric oxide (NO) and prostaglandin E2 (PGE2). will secrete a large amount.

Gene expression of proinflammatory cytokines and proteins is determined by nuclear factor-kappa B (NF-κB) and extracellular signal-regulated kinase (ERK), p38 kinase (p38), c- It is regulated by mitogen activated protein kinases (MAPKs) such as Jun NH2-terminal kinase (JNK). In addition, in the inflammatory process in the body, excessive nitric oxide (NO) and prostaglandin E2 (PGE2) are caused by inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2). Arguments are created NO is a highly reactive substance and is produced from L-arginine by NO synthetase (NOS), and NOS is divided into constituent NOS and induced NOS. In particular, it has been reported that iNOS produces a large amount of NO when stimulated by external stimuli or pro-inflammatory cytokines, and the excessively produced NO promotes inflammatory reactions such as vascular permeability and edema. Another major inflammatory mediator, COX, is an enzyme that promotes the conversion of arachidonic acid to prostaglandins after liberation of arachidonic acid from phospholipids in the cell membrane. It is expressed in large amounts in cells such as macrophages and monocytes by stimulation, and the resulting prostaglandins are involved in tumorigenesis by inhibiting tumor apoptosis and inducing angiogenesis. Therefore, for the regulation of macrophage-mediated inflammatory response, the expression of NO-producing enzyme iNOS, COX-2, a step enzyme of prostaglandin biosynthesis, and inflammatory cytokines, and their major signaling molecules MAPKs and NF-κB activity regulation is recognized as a key factor for regulating the inflammatory response.

All living things are known to produce antibacterial and antifungal substances for survival, and many studies are being made on microorganisms that produce antibacterial and antifungal substances. Studies to develop antibacterial or antifungal agents have been attempted for a long time.

Antibacterial substances kill microorganisms and are low in toxicity to humans or animals and have selective toxicity that are not inactivated by enzymes in the body. By inhibiting transport, cell wall biosynthesis, etc., it exerts an effect through a mechanism that inhibits the proliferation of microorganisms.

The main antibacterial substances developed so far can be divided into those derived from nature, such as microorganisms and plants, and those that are chemically synthesized. The first antibacterial substance isolated from nature was penicillin, discovered by Alexander Fleming in 1928. Many chemically synthesized antibacterial substances are used for the treatment of diseases caused by harmful bacteria. is the trend

As a technology related to a naturally-derived antibacterial or antifungal agent, high ginseng extract (patent application No. 10-1993-0006319), grapefruit extract (patent application No. 10-1993-0006320), fennel, magnolia, sessin, camphor and cloves Mixed extract (Patent Application No. 10-2002-0054685), Green Tea Polyphenol and Tea Tree Oil (Patent Application No. 10-2002-0028517), Sesbania Grandiprora Extract (Patent Application No. 10-2011-0015252) It has been reported so far that extracts of various plants or their fractions have antibacterial activity.

On the other hand, the immune response is a response to all substances that enter our body from the outside. In particular, since microorganisms, which are living organisms, are directly or indirectly related to the occurrence of diseases, the immune response to these is very important to the host. .

Due to the complexity of modern society and advanced industries, various mutagenic carcinogens are close to living space, and such mutant carcinogens accelerated the transformation of normal human genes or genes such as viruses. In the end, although drugs have been developed, the function of immune cells is weakened due to the modification of genes and the virus is getting stronger, causing more and more problems. As such, the weakening of immunity caused by modern people's eating habits or environmental pollution is easily exposed to infectious diseases such as measles and flu, cancer, congenital malformations, immune system defects, and many fatal diseases caused by the invasion of stronger viruses and foreign microorganisms. result in becoming

In particular, herpes zoster is a disease that occurs when the varicella-zoster virus usually causes chickenpox in childhood and remains dormant in the body and then reactivates. Usually within a few days, pathological symptoms in the form of rashes and characteristic blisters appear on the skin, accompanied by pain in the affected area. Shingles is rare in young people and usually occurs in adults over the age of 60 with weakened immune systems.

The causative agent is the herpes zoster virus. It is the same virus as the chickenpox virus, the cause of chickenpox in children. Once infected with the chickenpox virus in childhood, the virus does not completely disappear from the body even after having chickenpox. The chickenpox virus remaining in the body travels along nerves and remains dormant in ganglia. In this case, even if there is a virus in the body, people do not feel it, and there are no apparent pathological symptoms.

However, when the body's immune system is weakened, the chickenpox virus, which was dormant in the ganglion, travels down the nerve again to the skin, causing inflammation there, or in severe cases, the inflammation may spread throughout the body. The virus that causes these symptoms is the same as the chickenpox virus, but in this case it is called the herpes zoster virus. It is also collectively referred to as the varicella-zoster virus.

It often occurs in patients with human immunodeficiency virus (HIV) infection or in patients with weakened immune function due to organ transplantation or chemotherapy, and in this case, it can occur even at a young age. In most cases, pathological symptoms appear localized to the skin, but in patients with greatly weakened immunity, it may spread throughout the body and lead to death.

Herpes zoster occurs when the chickenpox virus, which was dormant in the ganglion, is reactivated. This area is accompanied by severe pain and paresthesia, and after red spots appear along the nerves, several blisters appear in groups. Blisters (blisters) have the same biopsy results as those seen in chickenpox patients.

Blisters change for 10 to 14 days, becoming cloudy as they fill with pus and then turning into scabs. An ulcer can form when a blister ruptures, such as by contact. Usually, after about 2 weeks, the scabs form and the symptoms improve. Even after all the pathological symptoms of the skin have improved, the affected area still hurts. Such shingles pain occurs in about 30% of elderly patients, and in some cases, the pain is severe enough to require the use of opioid analgesics.

Although shingles is treated with antiviral drugs, even if symptoms improve, the virus continues to exist in the body in a latent state, so if the virus is reactivated, shingles may occur again.

Accordingly, the present inventor continued research to develop a composition having antioxidative, anti-inflammatory, antibacterial and shingles improving effects, and a composition containing a mixture of yaknan and jindeukchal as an active ingredient has antioxidative, anti-inflammatory, antibacterial and shingles improving effects. The present invention was completed by finding that it has

Therefore, the technical problem to be solved in the present invention is to provide a composition having antioxidant, anti-inflammatory, antibacterial and herpes zoster improvement effects.

In order to solve the above technical problem, the present invention provides a pharmaceutical composition having antioxidant, anti-inflammatory, antibacterial and herpes zoster improvement effects, characterized in that it contains yaknan and Jindeukchal extract as active ingredients.

Preferably, the yaknan and Jindeukchal extracts are mixed in a weight ratio of 1:5 to 5:1.

In addition, the present invention provides a cosmetic composition having antioxidant, anti-inflammatory, antibacterial and herpes zoster improving effects, characterized in that it contains yaknan and Jindeukchal extract as active ingredients.

Preferably, the yaknan and Jindeukchal extracts are mixed in a weight ratio of 1:5 to 5:1.

In addition, the present invention provides a food composition having antioxidant, anti-inflammatory, antibacterial and shingles improving effects, characterized in that it contains yaknan and Jindeukchal extract as active ingredients.

Preferably, the yaknan and Jindeukchal extracts are mixed in a weight ratio of 1:5 to 5:1.

As such, the composition containing the extract of yaknan and Jindeukchal according to the present invention has an excellent DPPH free radical scavenging activity and thus has an antioxidant effect, and has an anti-inflammatory effect by inhibiting the production of NO and inflammatory cytokines. In addition, the composition of the present invention inhibits the production of IL (Interleukin)-6, IL-8, IL-1β, IL-4 and IL-13, which are cytokines expressed during an inflammatory reaction in human keratinocytes (HaCaT cells), , inhibits the activity of MAPKs, suppresses the expression of TARC and MDC, which are types of chemokines generated during inflammatory reactions, has the effect of regulating the expression of NF-κB and IκBα, and has an antibacterial effect against external stimuli or contaminants. It can prevent skin irritation. The pharmaceutical composition according to the present invention has excellent antiviral effect against varicella zoster virus. In addition, the composition according to the present invention has improved immunity and thus has an antiviral effect. In particular, the antiviral effect is excellent not only in the initial stage of infection with varicella zoster virus (at the time of chickenpox rash), but also during the incubation period and when shingles is confirmed after the incubation period. . That is, the pharmaceutical composition according to the present invention still has excellent antiviral effect even when administered 24 hours after infection with varicella zoster virus.

Hereinafter, the present invention will be described in more detail.

The present invention provides a composition having antioxidant, anti-inflammatory, antibacterial and shingles improving effects, characterized in that it contains glazed oran and gindeukchal extract as active ingredients.

According to one embodiment of the present invention, the composition may be a pharmaceutical composition, a cosmetic composition or a food composition.

Yaknan (Cremastra appendiculata), an active ingredient of the composition having antioxidant, anti-inflammatory, antibacterial and shingles improving effects of the present invention, is a perennial plant of the orchid family of the orchid family of the monocotyledonous plant Orchid family, has analgesic action, and has the effect of improving blood circulation It is also helpful in treating postpartum eohyeol, bruises, lymphadenitis, etc.

Siegesbeckia glabrescens, an active ingredient of the composition having antioxidant, anti-inflammatory, antibacterial and herpes zoster improving effects of the present invention, is an annual herb belonging to the family Compositae (Compositae), and is available for live use. When used, it removes moist heat and at the same time treats muscle pain or paralysis caused by moisture. When steamed in hwangju, it removes wind and moisture, protects the liver and kidneys, and strengthens bones and muscles. has the effect of It is mainly used for symptoms of paralysis of the extremities, pain and soreness of the knee, wasting of the mouth, and hemiplegia. It is also said to be effective in treating nasal congestion and nasal inflammation. In addition, there are records that it has been used for skin diseases such as eczema and tumors, and it is also used as a detoxifying effect for the symptoms of snake or insect bites.

As used herein, the term "extract" refers to a preparation obtained by squeezing a herbal medicine with an appropriate leachate and evaporating the leachate, but is not limited thereto. It may be a dried product obtained by drying, a crude product thereof, or a purified product.

The natural extract of the present invention can be prepared using general extraction methods, separation and purification methods known in the art. As the extraction method, a method such as hot water extraction, hot water extraction, cold extraction, reflux cooling extraction, or ultrasonic extraction may be used, but is not limited thereto.

According to a specific embodiment of the present invention, the natural extract is used by pulverizing a natural plant as it is, or after drying and pulverizing using a hot air dryer or freeze dryer, an extraction solvent such as water, anhydrous or hydrous lower alcohol having 1 to 3 carbon atoms and a solvent selected from the group consisting of a mixed solvent thereof can be extracted using an extraction solvent, preferably water or ethanol, and the amount of the extraction solvent is 2 to 20 times the dry weight of the natural plant, preferably 5 to It can be made 15 times by weight.

According to a specific embodiment of the present invention, the natural extract is pulverized and used as it is, or dried using a hot air dryer or freeze dryer and then pulverized using water or a mixture of water and alcohol at room temperature for 2 to 10 days; Preferably, extraction is carried out for 7 days, then filtered with filter paper and concentrated to separate water-soluble components and alcohol-soluble components, and mixing the water-soluble component and the alcohol-soluble component in a weight ratio of 5:4 to obtain each natural extract. there is.

Specifically, lyophilized and pulverized yaknan and jindeukchal extracts are thermally extracted using purified water at 90 to 110°C for 50 to 70 minutes, followed by filtration and concentration under reduced pressure to obtain extracts of yaknan and jindeukchal, respectively.

The yaknan and jindeukchal extracts may be those obtained by concentrating and lyophilizing the obtained extract to completely remove moisture. It can be dissolved in

According to one embodiment of the present invention, the extracts of Yaknan and Jindeukchal are mixed in a weight ratio of 1:5 to 5:1. At this time, when the yaknan extract and the extract of Jindeukchal are out of the above range, it is difficult to obtain antioxidant, anti-inflammatory, antibacterial and shingles improvement effects.

In the present invention, "antibacterial" means the action of inhibiting or controlling the growth and proliferation of contaminating microorganisms such as bacteria, fungi, mold, yeast, etc. means that

In the present invention, "anti-virus" refers to the ability to inhibit the infection of the viral particles including the herpes zoster-related virus and various subtypes and mutant viruses thereof into a host cell, that is, the cell membrane of the host cell. It refers to the ability to inhibit virus particles from adhering to and entering the cell. As a result, the virus interferes with the mechanism necessary for replication or propagation of virus particles using the host cell, thereby having antiviral activity.

According to one embodiment of the present invention, the composition containing yaknan and Jindeukchal extract as an active ingredient is a pharmaceutical composition for the treatment or prevention of diseases caused by varicella-zoster virus (VZV).

That is, the pharmaceutical composition according to the present invention is a composition having a pharmacological effect for treating or preventing chickenpox or herpes zoster, a disease caused by the varicella zoster virus, through an antiviral mechanism against the varicella zoster virus. The pharmaceutical composition according to the present invention kills the varicella zoster virus or inhibits the activity of the varicella zoster virus to treat or prevent varicella or herpes zoster, a disease caused by the varicella zoster virus, The varicella zoster virus is a varicella-zoster virus (VZV) belonging to the herpes virus group.

In addition, the composition according to the present invention does not have an antiviral effect only when the varicella zoster virus is initially infected. As it is 40-99%, excellent antiviral properties are still maintained even after a certain period of time after infection. Therefore, compared to the conventional pharmaceutical composition for varicella zoster antiviral, the antiviral effect is significantly reduced when 25 hours have elapsed after infection. is maintained excellently. In addition, the existing pharmaceutical composition for varicella zoster antiviral has significantly reduced antiviral properties even when confirmed as shingles after the incubation period, but the composition according to the present invention can be confirmed as shingles after the incubation period of the varicella zoster virus has passed. It continues to maintain excellent antiviral properties. In this case, the composition according to the present invention may have a death rate of 40-99% of the varicella zoster virus when the varicella zoster virus is reactivated as shingles after the incubation period has passed.

As used herein, the term 'comprising as an active ingredient' means including an amount sufficient to achieve the efficacy or activity of the extract of yaknan and Jindeukchal. In the present invention, the mixture of yaknan and Jindeukchal extract may be included in an amount of 1 to 90% by weight, preferably 2 to 80% by weight, more preferably 3 to 60% by weight based on the total weight of the composition. If it is less than the above range, the antioxidative, anti-inflammatory, antibacterial and herpes zoster improvement effects are insignificant, and if it exceeds the above range, the effect as described above does not continuously increase even if the content of the yaknan and Jindeukchal extract mixture increases.

The term "prevention" as used in the present invention means any action that inhibits or delays the occurrence, spread, and recurrence of antioxidant, anti-inflammatory, antibacterial and herpes zoster by administration of the composition according to the present invention, and is used in the present invention. The term “treatment” refers to any antioxidative, anti-inflammatory, antibacterial, and anti-inflammatory, antibacterial, and herpes-zoster-related disease progression that is delayed or stopped to improve symptoms, or beneficially alters antioxidant, anti-inflammatory, antibacterial and herpes zoster. means action. Those of ordinary skill in the art to which the present invention pertains, with reference to the data presented by the Korean Medical Association, etc. There will be.

According to one embodiment of the present invention, the present invention provides a pharmaceutical composition having anti-oxidation, anti-inflammatory, antibacterial and shingles improving effects, characterized in that it contains the extract of yaknan and Jindeukchal as active ingredients.

The pharmaceutical composition of the present invention may be prepared using pharmaceutically suitable and physiologically acceptable adjuvants in addition to the active ingredients, and the adjuvants include excipients, disintegrants, sweeteners, binders, coating agents, swelling agents, lubricants, A lubricant or flavoring agent may be used.

The pharmaceutical composition may be preferably formulated as a pharmaceutical composition by including one or more pharmaceutically acceptable carriers in addition to the active ingredients described above for administration.

Formulations of the pharmaceutical composition may be granules, powders, tablets, coated tablets, capsules, suppositories, solutions, syrups, juices, suspensions, emulsions, drops or injectables. For example, for formulation in the form of a tablet or capsule, the active ingredient may be combined with an orally, non-toxic, pharmaceutically acceptable inert carrier such as ethanol, glycerol, water, and the like. In addition, if desired or required, suitable binders, lubricants, disintegrants and color-developers may also be included in the mixture. Suitable binders include, but are not limited to, starch, gelatin, natural sugars such as glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tracacanth or sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride, and the like. Disintegrants include, but are not limited to, starch, methyl cellulose, agar, bentonite, xanthan gum, and the like.

In the composition formulated as a liquid solution, acceptable pharmaceutical carriers are sterile and biocompatible, and include saline, sterile water, Ringer's solution, buffered saline, albumin injection, dextrose solution, maltodextrin solution, glycerol, ethanol and One or more of these components may be mixed and used, and other conventional additives such as antioxidants, buffers, and bacteriostats may be added as needed. In addition, diluents, dispersants, surfactants, binders and lubricants may be additionally added to form an injectable formulation such as an aqueous solution, suspension, emulsion, etc., pills, capsules, granules or tablets.

Furthermore, it can be preferably formulated according to the ingredients using a method disclosed in Remington's Pharmaceutical Science, Mack Publishing Company, Easton PA by an appropriate method in the art.

The pharmaceutical composition of the present invention may be administered orally or parenterally, and in the case of parenteral administration, it may be administered by intravenous injection, subcutaneous injection, intramuscular injection, intraperitoneal injection, transdermal administration, etc., preferably oral administration. .

A suitable dosage of the pharmaceutical composition of the present invention varies depending on factors such as formulation method, administration mode, age, weight, sex, pathological condition, food, administration time, administration route, excretion rate, and response sensitivity of the patient, An ordinarily skilled physician can readily determine and prescribe a dosage effective for the desired treatment or prophylaxis. According to a preferred embodiment of the present invention, the daily dose of the pharmaceutical composition of the present invention is 0.001-10 g/kg.

The pharmaceutical composition of the present invention is prepared in unit dosage form by formulating using a pharmaceutically acceptable carrier and/or excipient according to a method that can be easily carried out by a person of ordinary skill in the art to which the present invention pertains. or it may be prepared by incorporation into a multi-dose container. In this case, the formulation may be in the form of a solution, suspension, or emulsion in oil or an aqueous medium, or may be in the form of an extract, powder, granule, tablet or capsule, and may additionally include a dispersant or stabilizer.

According to one embodiment of the present invention, there is provided a cosmetic composition having antioxidative, anti-inflammatory, antibacterial and shingles improving effects, characterized in that it contains yaknan and Jindeukchal extract as active ingredients.

To the cosmetic composition of the present invention, in addition to the active ingredients, components commonly added to the cosmetic composition, such as antioxidants, stabilizers, solubilizers, vitamins, pigments, and fragrances, may be additionally added to conventional adjuvants and carriers.

The cosmetic composition of the present invention may be prepared in any formulation conventionally prepared in the art, for example, a solution, suspension, emulsion, paste, gel, cream, lotion, powder, soap, surfactant-containing cleansing , oil, powder foundation, emulsion foundation, wax foundation, spray, etc., but is not limited thereto. More specifically, it may be prepared in the form of a nourishing cream, an astringent lotion, a softening lotion, a lotion, an essence, a nourishing gel or a massage cream.

When the formulation of the present invention is a paste, cream or gel, animal oil, vegetable oil, wax, paraffin, starch, gum tracanth, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide, etc. are used as carrier components. can be

When the formulation of the present invention is a powder or a spray, toss, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component, and in particular, in the case of a spray, additional chlorofluorohydrocarbon, propane /may contain propellants such as butane or dimethyl ether.

When the formulation of the present invention is a solution or emulsion, a solvent, solubilizer or emulsifier is used as a carrier component, for example, water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1 ,3-butylglycol oil, glycerol fatty esters, fatty acid esters of polyethylene glycol or sorbitan.

When the formulation of the present invention is a suspension, as a carrier component, a liquid diluent such as water, ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, microcrystals Adult cellulose, aluminum metahydroxide, bentonite, agar or gum tracanth may be used.

When the formulation of the present invention is a surfactant-containing cleansing agent, aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyltaurate, sarcosinate, fatty acid amide as carrier components Ether sulfate, alkylamidobetaine, fatty alcohol, fatty acid glyceride, fatty acid diethanolamide, vegetable oil, lanolin derivative or ethoxylated glycerol fatty acid ester and the like may be used.

The cosmetic composition of the present invention further comprises a fatty substance, an organic solvent, a solubilizer, a thickening agent and a gelling agent, an emollient, an antioxidant, a suspending agent, a stabilizer, a foaming agent, a fragrance, a surfactant, a film forming agent, water, Ionic or nonionic emulsifiers, fillers, sequestering and chelating agents, preservatives, vitamins, blocking agents, wetting agents, essential oils, dyes, pigments, hydrophilic or lipophilic actives, lipid vesicles or any conventionally used in cosmetics It may contain adjuvants commonly used in the field of cosmetics or dermatology, such as other ingredients of And, the above ingredients may be introduced in an amount generally used in the field of dermatology.

According to one embodiment of the present invention, the present invention provides a food composition having antioxidant, anti-inflammatory, antibacterial and herpes zoster improving effects, characterized in that it contains yaknan and Jindeukchal extract as active ingredients.

In one embodiment of the present invention, the food composition may be a tablet, capsule, powder, granule, liquid, pill, liquid, syrup, juice, suspension, emulsion, or drop. For formulation in the form of, for example, tablets or capsules, the active ingredient may be combined with an orally, non-toxic, acceptable inert carrier such as ethanol, glycerol, water, and the like. In addition, if desired or required, suitable binders, lubricants, disintegrants and color-developers may also be included in the mixture. Suitable binders include, but are not limited to, starch, gelatin, natural sugars such as glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tracacanth or sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride, and the like. Disintegrants include, but are not limited to, starch, methyl cellulose, agar, bentonite, xanthan gum, and the like. In the composition formulated as a liquid solution, acceptable pharmaceutical carriers are sterile and biocompatible, and include saline, sterile water, Ringer's solution, buffered saline, albumin injection, dextrose solution, maltodextrin solution, glycerol, ethanol and One or more of these components may be mixed and used, and other conventional additives such as antioxidants, buffers, and bacteriostats may be added as needed. In addition, diluents, dispersants, surfactants, binders and lubricants may be additionally added to form an injectable formulation such as an aqueous solution, suspension, emulsion, etc., pills, capsules, granules or tablets.

In addition, the food composition of the present invention may be used as a functional food or added to various foods. Foods to which the composition of the present invention can be added include, for example, tea, beverages, meat, chocolate, jelly, foods, confectionery, pizza, ramen, other noodles, gums, candies, ice cream, alcoholic beverages, vitamin complexes, and There are health supplements, etc.

In addition, the food composition includes various nutrients, vitamins, minerals (electrolytes), synthetic flavoring agents and natural flavoring agents in addition to the active ingredients, coloring agents and thickeners (cheese, chocolate, etc.), pectic acid and salts thereof, alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated beverages, and the like.

The health functional food of the present invention can be manufactured and processed in the form of tablets, capsules, powders, granules, liquid sticks, pills, and the like.

In the present invention, the term "health functional food" refers to a food manufactured and processed using raw materials or ingredients useful for the human body according to the Health Functional Food Act, and controls nutrients for the structure and function of the human body or physiologically It means taking for the purpose of obtaining useful effects for health purposes, such as action.

The health functional food of the present invention may contain normal food additives, and unless otherwise specified, whether it is suitable as a food additive is related to the item according to the general rules and general test method of food additives approved by the Food and Drug Administration. It is judged according to the standards and standards.

The items listed in the Food Additives Codex include, for example, chemical compounds such as ketones, glycine, calcium citrate, nicotinic acid, and cinnamic acid; natural additives such as persimmon pigment, licorice extract, crystalline cellulose, high pigment, and guar gum; and mixed preparations such as sodium L-glutamate preparations, noodles-added alkalis, preservatives, and tar dye preparations.

For example, for health functional food in tablet form, a mixture obtained by mixing an active ingredient with an excipient, a binder, a disintegrant and other additives is granulated in a conventional manner, followed by compression molding by adding a lubricant, or the mixture directly Compression molding is possible. In addition, the health functional food in the form of tablets may contain a corrosive agent and the like, if necessary.

Among health functional foods in the form of capsules, hard capsules can be prepared by filling a mixture of the active ingredient of the present invention with additives such as excipients in conventional hard capsules, and soft capsules are prepared by mixing the extract with additives such as excipients. The mixture can be prepared by filling a capsule base such as gelatin. The soft capsules may contain a plasticizer such as glycerin or sorbitol, a colorant, a preservative, and the like, if necessary.

A health functional food in the form of a ring can be prepared by molding a mixture of the active ingredient of the present invention with an excipient, a binder, a disintegrant, etc. by a known method, Alternatively, the surface may be coated with a material such as starch or talc.

A health functional food in the form of granules can be prepared in a granular form by a conventionally known method by mixing the active ingredient of the present invention with an excipient, binder, disintegrant, etc. there is.

In the preparation of the composition of the present invention, as a food composition, in addition to the active ingredient introduced in the present invention, various flavoring agents and natural carbohydrates may be added as additional ingredients, such as a commonly used food composition, and physiologically acceptable supplements may be used. In addition, the adjuvant may include an excipient, a sweetener, a coating agent, an expanding agent, a lubricant, a binder, or a flavoring agent.

The food composition of the present invention may be used as a functional food or added to various foods. Foods to which the composition added in the present invention can be added include, for example, chocolates, beverages, foods, snacks, noodles, gums, candies, and health supplements.

Health functional food in the present invention may include commonly used food additives, and food additives are determined according to standards and standards in accordance with the general rules and general test methods of the Food Additives Code approved by the Food and Drug Administration.

As such, the composition containing the extract of yaknan and Jindeukchal according to the present invention has an excellent DPPH free radical scavenging activity and thus has an antioxidant effect, and has an anti-inflammatory effect by inhibiting the production of NO and inflammatory cytokines. In addition, the composition of the present invention inhibits the production of IL (Interleukin)-6, IL-8, IL-1β, IL-4 and IL-13, which are cytokines expressed during an inflammatory reaction in human keratinocytes (HaCaT cells), , inhibits the activity of MAPKs, suppresses the expression of TARC and MDC, which are types of chemokines generated during inflammatory reactions, has the effect of regulating the expression of NF-κB and IκBα, and has an antibacterial effect against external stimuli or contaminants. It can prevent skin irritation. The pharmaceutical composition according to the present invention has excellent antiviral effect against varicella zoster virus. In addition, the composition according to the present invention has improved immunity and thus has an antiviral effect. In particular, the antiviral effect is excellent not only in the initial stage of infection with varicella zoster virus (at the time of chickenpox rash), but also during the incubation period and when shingles is confirmed after the incubation period. . That is, the pharmaceutical composition according to the present invention still has excellent antiviral effect even when administered 24 hours after infection with varicella zoster virus.

Hereinafter, examples and the like will be described in detail to help the understanding of the present invention. However, the embodiments according to the present invention may be modified in various other forms, and the scope of the present invention should not be construed as being limited to the following examples. The embodiments of the present invention are provided to more completely explain the present invention to those of ordinary skill in the art.

<Preparation Example 1> Preparation of yaknan extract

1 kg of fruiting body powder obtained by freeze-drying and pulverizing the eggplant was put in purified water and extracted with hot water at 100° C. for 1 hour. The extract was filtered under reduced pressure with Advantec No. 2 (110mm) filter paper to remove insoluble substances, and then concentrated under reduced pressure at 40° C. using a concentrator equipped with a cooling condenser. In order to completely remove the solvent of the extract concentrated under reduced pressure, 0.5 L of purified water was added to suspend the extract, and then the extract was obtained using a freeze dryer.

<Preparation Example 2> Preparation of Jindeukchal extract

1 kg of fruiting powder obtained by freeze-drying and pulverizing Jindeukchal was added to purified water and extracted with hot water at 100° C. for 1 hour. The extract was filtered under reduced pressure with Advantec No. 2 (110mm) filter paper to remove insoluble substances, and then concentrated under reduced pressure at 40° C. using a concentrator equipped with a cooling condenser. In order to completely remove the solvent of the extract concentrated under reduced pressure, 0.5 L of purified water was added and suspended, and then the extract was obtained using a freeze dryer.

<Example 1> Preparation of composition containing Yaknan and Jindeukchal extract as active ingredients

A composition was prepared in which the yaknan extract and Jindeukchal extract obtained in Preparation Examples 1 and 2 were mixed in a weight ratio of 1:1.

<Comparative Example 1>

A composition containing only the yaknan extract of Preparation Example 1 was prepared.

<Comparative Example 2>

A composition comprising only the extract of Jindeukchal of Preparation Example 2 was prepared.

<Test Example 1> Measurement of antioxidant effect

(1) DPPH (1-1-diphenyl-2-picryl-hydrazyl) radical electron donating ability measurement

100 μl of DPPH solution (5x10-4 M) was added to 100 μl of the composition obtained in Example 1 for each concentration and reacted for 30 minutes in an incubator at 25° C., and then absorbance was measured at 540 nm using a microplate counter. As a control, L-ascorbic acid was used. Electron donating ability was expressed as the absorbance decrease rate of the sample solution and the non-additive group.

DPPH electron donating ability L-Ascorbic Acid 100 Composition of Example 1 98.2 Composition of Comparative Example 1 33.2 Composition of Comparative Example 2 42.5

As shown in Table 1, the composition of Example 1 according to the present invention exhibited a high antioxidant effect of 98.2%.

(2) Measurement of ABTS cation radical scavenging activity

7mM 2,2-azino-bis(3-ethyl-benthiazoline-6-sulfonic acid) and 2.4mM potassium persulfate were mixed and left at room temperature for 24 hours to form ABTS+, diluted with ethanol and sampled in 100μl of ABTS+ After adding 100 μl and leaving it for 1 minute, absorbance was measured at 732 nm, and L-ascorbic acid was used as an experimental control. The radical scavenging ability was expressed as the concentration value of the sample required for reduction by 1/2.

ABTS cation radical scavenging ability L-Ascorbic Acid 100 Composition of Example 1 85.6 Composition of Comparative Example 1 35.1 Composition of Comparative Example 2 41.2

As a result of ABTS+ measurement, the composition of Example 1 according to the present invention exhibited a high antioxidant effect of 85.6%.

<Test Example 2> Measurement of antibacterial activity

Propionibacterium acnes strain (KCTC 5012, culture condition: anaerobic, 37° C., 48 h), known as the causative bacteria of acne, was used in the composition prepared in Example 1 in RCM medium, Staphylococcus epidermidis (Staphylococcus) epidermidis) strain (KCTC 1917, culture condition: aerobic, 30°C, 48h) is NB medium and Staphylococcus aureus strain (KCTC 3881, culture condition: anaerobic, 37°C, 24h) is NA medium The growth inhibitory efficacy of each strain was verified by culturing using.

By mixing the liquid medium for each strain and the composition prepared in Example 1, respectively, three strains were prepared with an initial number of bacteria of 1ㅧ10 ⁶ CFU/ml, and a microbial reduction efficacy test was performed. Each of the three prepared strains, including the control group (empty test group), was inoculated and cultured under optimal conditions for each strain. Samples were collected every 0, 1, and 24 hours, diluted 10-fold with sterile saline, and spread on an agar medium. .

After plated plates were cultured under optimal conditions, the reduction rate was confirmed by confirming and counting typical colonies, thereby confirming the reduction efficacy against three types of microorganisms. For comparative verification, salicylic acid (Comparative Example 3) and tea tree oil (Comparative Example 4), which are antibacterial substances well known for their antibacterial effect against conventional acne-causing bacteria, were used.

P. acnes
KCTC 5012 S. epidermidis KCTC 1917 S. aureus
KCTC 3881 CFU/ml decrease rate CFU/ml decrease rate CFU/ml decrease rate control 2.7x10 ⁶ increase 0.8x10 ⁵ increase 1.0x10 ⁵ increase Comparative Example 3 <10 ≥99.9 <10 ≥99.9 <10 ≥99.9 Comparative Example 4 2.8x10 ⁶ 77.9 3.8x10 ⁶ increase 4.9x10 ⁶ increase Example 1 <10 ≥99.9 <10 ≥99.9 <10 ≥99.9

As a result of the experiment, as shown in Table 3, the composition prepared in Example 1 was observed to have excellent antibacterial activity at the level of salicylic acid of Comparative Example 3, and it was observed that the antibacterial activity was rather high compared to the tea tree oil of Comparative Example 4.

<Test Example 3> Evaluation of T-lymphocyte and B-lymphocyte proliferation capacity in the mouse spleen

The effect of the composition of Example 1 of the present invention on the proliferation of T-lymphocytes and B-lymphocytes, which are immune cells in the spleen, was investigated.

As the experimental animals, 7-week-old female C57BL/6 mice (Orient Bio, Gapyeong-gun, Gyeonggi-do, Korea) were used, and a total of 30 mice were used, 6 in each test group. The purchased animals were used for the test after an adaptation period for one week in a laboratory with a temperature of 21±3℃, a relative humidity of 50±5%, and an illumination of 200-300 Lux. No weight change or adverse reactions were observed. All samples were suspended using physiological saline (Chungwae Pharmaceutical, Korea), and the samples were orally administered at 100 mg/kg once a day for a total of 7 days. The normal control group was administered the same amount of physiological saline in the same way. The spleen was removed from the experimental animal after administration, and splenocytes were separated, and then the cells were inoculated in a 96-well plate at 5X10 ⁵ cells/well. Thereafter, a concanavalin A (Con A; Sigma Aldrich, St. Louis, MO, USA) solution at a concentration of 5 μg/ml was added to each well for T-lymphocyte proliferation measurement, and 15 μg/ml concentration for B-lymphocyte proliferation measurement. of LPS (Sigma Aldrich, St. Louis, MO, USA) solution was added by 10 μl, respectively, and reacted at 37° C., 5% CO 2 in an incubator for 72 hours. After the reaction was completed, 20 μl of cell titer solution (Promega, USA) was added to the cell culture medium, followed by incubation for 4 hours, followed by fluorescence Multi-Detection Reader ((BIO-TEK Instruments Inc., Power wave X340, Winooski, VT, USA). ) was used to measure the absorbance at 490 nm.

As a result, as shown in Table 4 below, it was confirmed that the degree of proliferation of T-lymphocytes and B-lymphocytes was increased in the group administered with the composition of Example 1 of the present invention.

control Example 1 Comparative Example 1 Comparative Example 2 T lymphocytes 12 62 16 13 B lymphocytes 8 51 9 10

<Test Example 4> Measurement of NO inhibition induced by LPS in macrophage line (RAW264.7)

In macrophages, when an inflammatory response is triggered by an external stimulus such as LPS, various pathological responses that secrete NO, produce various substances such as inflammatory cytokines, and regulate the inflammatory response occur. The anti-inflammatory efficacy was investigated by treating the composition in RAW264.7 cells induced with LPS.

The stabilized NO oxide, NO ₂ (Nitrite), was measured using the Griess reaction. First, a mouse macrophage line (RAW264.7) was dispensed in a 96-well plate at a rate of 5 X 10 ⁴ cells/100 μl per well, followed by CO ₂ incubation for 24 hours. LPS (lipopolysaccharide) was treated at a concentration of 1 μg/ml and incubated for 1 hour in CO₂, then the prepared composition sample was treated and incubated in CO₂ for 24 hours. Then, each culture supernatant was placed in a 96-well plate and the same amount of Griess reagent (0.1% N-1-naphtyl-ethylendiamine in H ₂ O : 1% sulfanilamide in 5% H ₃ PO ₄ = 1:1) was added. After reacting for 10 minutes, absorbance was measured at 550 nm with a microplate reader. The concentration of NO ₂ (Nitrite) was calculated by comparing with a standard curve obtained by diluting NaNO ₂ (sodium nitrite) two-fold from 100 μM to 0.7 μM. LPS was used as a positive control.

Control LPS DMSO Example 1 Comparative Example 1 Comparative Example 2 N.D. 9.57±0.0 10.20±0.5 4.21±0.4 14.12±0.3 15.13±0.4

As a result, it was confirmed that the composition of Example 1 of the present invention was excellent in the inhibition rate of NO production.

<Test Example 5> Measuring the effect on inflammatory cytokines (Cytokine) induced by LPS in macrophage cell line (RAW 264.7)

RAW264.7 macrophages were aliquoted in a 24-well plate at a volume of 5 X 10 ⁵ cells/1ml per well and incubated with CO₂ for 24 hours. After that, the wells were treated with LPS (lipopolysaccharide) at a concentration of 1 μg/ml and the composition was incubated with CO₂ for 24 hours. Then, the cell culture supernatant was harvested. The cytokines included in the supernatant, IL-6, TNF-α, GM-CSF, and IL-1β, were measured using an enzyme-linked immunosorbent assay (ELISA). That is, the primary antibody (capture antibody) was diluted in a coating solution (0.1 M sodium carbonate, pH 9.5) in a plate-bottom micro-well, dispensed at 100 μl/well, and incubated at 4° C. overnight, followed by a washing solution (0.05% Tween 20/PBS). The washed microwells were blocked with PBS to which 10% FBS was added, and the culture supernatant collected in the experiment was diluted at an appropriate ratio, then dispensed into each well and reacted at room temperature. Then, after reacting with 100 μl/well of the biotin-attached secondary antibody at room temperature for a certain period of time, 100 μl/well of avidin-peroxidase (enzyme reagent) was added. Finally, a substrate (3,3′,5,5′-Tetramethylbenzidine Liquid Substrate, H ₂ O ₂ ) was added to develop color and then measured using a microplate reader. The measured concentrations of IL-6, TNF-α, GM-CSF, and IL-1β were converted using a standard curve.

The results are shown in Table 6 below.

Cytokines Control LPS DMSO Example 1 IL-1β N.D. 513.44±4.4 507.19±4.4 100.11±1.3 GM-CSF N.D. 1801.65±58.4 1723.14±64.3 131.17±2.1 IL-6 N.D. 18.98±0.5 18.19±0.1 0.85±0.2 TNF-α N.D. 8.28±0.1 9.47±0.2 2.63±1.4

As can be seen from the results, as a result of confirming the effect of the composition of Example 1 on the inflammatory cytokines induced by LPS in RAW 264.7 cells, IL-6, IL-1β, TNF-α, GM-CSF were all statistically It was confirmed that it significantly inhibits pro-inflammatory cytokines.

<Test Example 6> Antiviral effect evaluation through measurement of inhibition of plaque formation

HFF cells grown as monolayers were infected with varicella zoster virus at an MOI of 0.01. After one hour, the virus was removed and the composition of Example 1 was treated and then cultured for 24 hours. After trypsin treatment, remove the cells, put them in normal HFF 1:1, and incubate for 4-5 days. The number of plaques was measured by fixing the cells with a 4% formaldehyde fixative and staining the cells with 0.05% crystal violet.

As a result of the measurement, it was confirmed that the proliferation of varicella zoster virus was inhibited as the number of plaques decreased by more than two times when treated with the drug compared to the control group that was not treated with the drug.

<Test Example 7> After 25 hours after infection with varicella zoster virus, evaluation of antiviral effect by measuring inhibition of plaque formation

The experiment was performed in the same manner as in Test Example 6, except that HFF cells grown in a monolayer were infected with varicella zoster virus at an MOI of 0.01, and then after 25 hours, the virus was removed and the rest of the experiment was performed to determine the number of plaques. measured.

As a result of the measurement, the composition of Example 1 of the present invention showed excellent antiviral properties as in the initial stage of infection even when the remaining experiments were performed after 25 hours of infection. In particular, in the composition of Example 1, 25-30 hours after infection, the death rate of the varicella zoster virus may correspond to 40-99%.

<Test Example 8> Evaluation of antiviral effect on varicella zoster virus reactivated with herpes zoster after incubation period

An experiment was conducted to determine whether the composition of Example 1 still had an antiviral effect even when the varicella zoster virus was reactivated to herpes zoster after the incubation period. This experiment was conducted with a virus obtained from a confirmed patient with herpes zoster.

As a result, it was confirmed that the composition of Example 1 according to the present invention was still excellent in antiviral effect even when it was confirmed as herpes zoster after the incubation period.

That is, through these results, the composition of Example 1 according to the present invention not only still had an antiviral effect even after 25 hours after herpes zoster virus infection, but also had an antiviral effect even when confirmed as herpes zoster past the incubation period. Excellent was confirmed. Therefore, the composition of the present invention has excellent antiviral effect even after the incubation period has passed compared to the existing varicella zoster antiviral agents.

<Test Example 9> Herpes zoster clinical trial

(1) Measurement of clinical trials for an 82-year-old male

A clinical trial was conducted on an 82-year-old male who complained of pain in the back, shoulder, and ribs after treatment for herpes zoster at a dermatology clinic, which made it difficult to sleep at night. Shingles is a disease that occurs when the varicella-zoster virus causes chickenpox in childhood and remains dormant in the body and then reactivates. Viruses remaining in the body move along nerves and dormant in ganglia, and when immunity is weakened, painful inflammation occurs in the skin. The herpes zoster improvement composition according to the present invention was taken once a day b.i.d for 3 days, and then taken once a day for 7 days more. After 10 days, the pain completely disappeared and herpes zoster was completely cured.

(2) 60 years old female clinical trial measurement

A clinical trial was conducted on a 60-year-old woman suffering from herpes zoster who complained of inability to sleep due to pain despite taking prescription drugs. The herpes zoster improvement composition according to the present invention was taken once a day t.i.d for 3 days. After 3 days, the traces of herpes zoster remained, but the pain completely disappeared.

<Test Example 10> Cytotoxicity test

RAW 264.7 cells, a macrophage cell line, were purchased from the Korea Cell Line Bank (KTCC) and used in RPMI 1640 medium containing 10% FBS (fetalbovine serum), 1% antibiotic, and 2-ME (2-mercaptoethanol) at 37°C, 4%. Incubated in an incubator controlled in CO ₂ .

The macrophage cell line RAW264.7 of the cultured mouse was dispensed in a 96-well plate at a rate of 5 X 10 ⁴ cells/100 μl per well, followed by CO ₂ incubation for 24 hours. After 1 hour after treatment with LPS (lipopolysaccharide) at a concentration of 1 μg/ml, the sample of the composition prepared in Example 1 was treated and CO ₂ cultured for 24 hours. Then, 100 μl of each culture supernatant was removed, and 10 μl of CCK-8 reagent was treated and incubated for 3 hours with CO ₂ , and then absorbance was measured at 450 nm using a microplate reader.

The results are shown in Table 7 below.

Control LPS Composition of Example 1 100.00±0.2 97.64±0.9 99.78±5.4

As can be seen from the results, the test sample was treated with LPS-activated macrophage cell line (RAW264.7) to check whether the sample exhibits cytotoxicity, and as a result, it was confirmed that the composition of the present invention does not exhibit toxicity.

<Test Example 11> Safety confirmation experiment on human skin

In order to confirm that the composition of the present invention is safe for human skin, a skin safety verification experiment was performed. To verify the safety of the skin, a conventional cumulative skin irritation test was performed.

For 30 healthy adults, the composition prepared in Example 1 was applied to the upper forearm region 9 times every other day, cumulatively for 24 hours, to determine whether the composition of the present invention stimulates the skin.

As the patching method, a pin chamber (Finn chamber, Epitest Ltd, Finland) was used, and 15 μl of each cosmetic was dropped into the chamber, followed by patching. The degree of the reaction shown on the skin each time was scored using Equation 1 below, and the results are shown in Table 8. A general commercial cosmetic was used as a control.

In the reactivity, ± 1 point, + 2 points, and ++ 4 points are given, and when the average reactivity is less than 3, it is judged as a safe composition.

test substance Number of subjects who responded Average
reactivity 1 week 2 weeks 3 weeks Primary Secondary tertiary 4th 5th 6th 7th 8th 9th ±/++/++ ±/++/++ ±/++/++ ±/++/++ ±/++/++ ±/++/++ ±/++/++ ±/++/++ ±/++/++ control One/-/- 0/-/- ---/- ---/- ---/- ---/- ---/- ---/- ---/- 0.09 Example 1 0/-/- 0/-/- ---/- ---/- ---/- ---/- ---/- ---/- ---/- 0.00

As shown in Table 8, in the composition of Example 1, the number of persons corresponding to ±, + and ++ was 0, 0, and 0, respectively, and the average reactivity was 0.00, 0.00, and 0.00, respectively. Therefore, since the average reactivity shows a reactivity of 3 or less, the composition of the present invention was judged to be a safe material for human skin that does not show a distinct cumulative stimulation pattern.

Examples of formulations of pharmaceutical preparations using the composition of the present invention are exemplified below.

<Preparation Example 1> Preparation of pharmaceutical formulations

<1-1> Preparation of injection

300 mg of the composition of Example 1

Sodium metabisulfite 3.0 mg

Methylparaben 0.8 mg

Propylparaben 0.1 mg

Appropriate amount of sterile distilled water for injection

The above ingredients were mixed and prepared to have a final volume of 2 ml by a conventional method, filled in an ampoule, and sterilized to prepare an injection.

<1-2> Preparation of powder

10 mg of the composition of Example 1

1 g lactose

The above ingredients were mixed and filled in an airtight cloth to prepare a powder.

<1-3> Preparation of tablets

0.1 mg of the composition of Example 1

100 mg cornstarch

100 mg lactose

2 mg magnesium stearate

After mixing the above ingredients, tablets were prepared by tableting according to a conventional manufacturing method of tablets.

<1-4> Preparation of capsules

0.1 mg of the composition of Example 1

100 mg cornstarch

100 mg lactose

2 mg magnesium stearate

After mixing the above ingredients, the capsules were prepared by filling in gelatin capsules according to a conventional manufacturing method of capsules.

<1-5> Preparation of the ring

1 mg of the composition of Example 1

1.5 g lactose

1 g of glycerin

0.5 g of xylitol

After mixing the above components, it was prepared so as to be 4 g per 1 ring according to a conventional method.

<1-6> Preparation of granules

0.15 mg of the composition of Example 1

50 mg soybean extract

glucose 200 mg

Starch 600 mg

After mixing the above ingredients, 100 mg of 30% ethanol was added and dried at 60° C. to form granules, and then filled in a bag.

Examples of formulations of cosmetics using the composition of the present invention are exemplified below.

<Formulation Example 2> Cosmetic formulation

<2-1> Manufacture of softened lotion

A softening lotion containing the composition of Example 1 as an active ingredient with a composition as shown in Table 9 below was prepared according to a conventional method.

ingredient weight% Composition of Example 1 0.01 glycerin 3.0 butylene glycol 2.0 propylene glycol 2.0 carboxyvinyl polymer 0.1 ethanol 10.0 arginine 0.08 Preservatives, micro pigments, micro fragrances and micro-purified water 82.79 sum 100.0

<2-2> Preparation of nutritional lotion

A nutritional lotion containing the composition of Example 1 as an active ingredient with a composition as shown in Table 10 below was prepared according to a conventional method.

ingredient weight% Composition of Example 1 0.01 beeswax 4.0 Polysorbate 60 1.5 Sorbitan sesquioleate 0.5 liquid paraffin 5.0 squalane 5.0 Caprylic/Capric Triglycerides 5.0 glycerin 3.0 butylene glycol 3.0 propylene glycol 3.0 carboxyvinyl polymer 0.1 arginine 0.15 Preservatives, micro pigments, micro fragrances and micro-purified water 69.69 sum 100.0

<2-3> Preparation of nourishing cream

As shown in Table 11 below, a nutritional cream containing the composition of Example 1 as an active ingredient was prepared according to a conventional method.

ingredient weight% Composition of Example 1 0.01 beeswax 10.0 Polysorbate 60 1.5 Sorbitan sesquioleate 0.5 liquid paraffin 10.0 squalane 5.0 Caprylic/Capric Triglycerides 5.0 glycerin 5.0 butylene glycol 3.0 propylene glycol 3.0 arginine 0.18 Preservatives, micro pigments, micro fragrances and micro-purified water 56.79 sum 100.0

<2-4> Preparation of massage cream

A massage cream containing the composition of Example 1 as an active ingredient with a composition as shown in Table 12 below was prepared according to a conventional method.

ingredient weight% Composition of Example 1 0.01 beeswax 10.0 Polysorbate 60 1.5 Sorbitan sesquioleate 0.8 liquid paraffin 40.0 squalane 5.0 Caprylic/Capric Triglycerides 4.0 glycerin 5.0 butylene glycol 3.0 propylene glycol 3.0 arginine 0.2 Preservatives, micro pigments, micro fragrances and micro-purified water 27.49 sum 100.0

<2-5> Preparation of pack

A pack containing the composition of Example 1 as an active ingredient with a composition as shown in Table 13 below was prepared according to a conventional method.

ingredient weight% Composition of Example 1 0.01 polyvinyl alcohol 13.0 Sodium Carboxymethylcellulose 0.2 allantoin 0.1 ethanol 5.0 nonylphenyl ether 0.3 Preservatives, micro pigments, micro fragrances and micro-purified water 81.39 sum 100.0

Examples of formulations of health drinks using the composition of the present invention are exemplified below.

<Production Example 3> Preparation of health drink

<3-1> Manufacturing of health drinks

By homogeneously mixing 0.5 g of the composition of Example 1 of the present invention with auxiliary materials such as high fructose (0.5%), oligosaccharide (2%), sugar (2%), salt (0.5%), and water (75%), After sterilization, it was prepared by packaging it in a small packaging container such as a glass bottle or a plastic bottle.

<3-2> Preparation of vegetable juice

0.5 g of the composition of Example 1 of the present invention was added to 1,000 mL of tomato or carrot juice to prepare vegetable juice.

<3-3> Preparation of fruit juice

Fruit juice was prepared by adding 0.1 g of the composition of Example 1 of the present invention to 1,000 mL of apple or grape juice.

Although the composition ratio is prepared by mixing ingredients suitable for relatively favorite beverages in a preferred embodiment, the mixing ratio may be arbitrarily modified according to regional and national preferences such as demand class, demanding country, and use.

Examples of formulations of health food using the composition of the present invention are exemplified below.

<Production Example 4> Preparation of health food

Foods containing the composition of Example 1 of the present invention as an active ingredient were prepared as follows.

<4-1> Manufacturing of wheat flour food

0.5 to 5.0 parts by weight of the composition of Example 1 of the present invention was added to wheat flour, and breads, cakes, cookies, crackers and noodles were prepared using this mixture.

<4-2> Preparation of soups and gravies

By adding 0.1 to 5.0 parts by weight of the composition of Example 1 of the present invention to soup and broth, processed meat products for health promotion, soup and broth of noodles were prepared.

<4-3> Preparation of ground beef

Ground beef for health promotion was prepared by adding 10 parts by weight of the composition of Example 1 of the present invention to ground beef.

<4-4> Production of dairy products

5 to 10 parts by weight of the composition of Example 1 of the present invention was added to milk, and various dairy products such as butter and ice cream were prepared using the milk.

<4-5> Manufacture of wire type

Brown rice, barley, glutinous rice, and barley radish were pregelatinized by a known method and dried, and then roasted and prepared as a powder having a particle size of 60 mesh with a grinder.

Black soybeans, black sesame, and perilla were also steamed and dried by a known method, and then roasted and prepared into powder having a particle size of 60 mesh with a grinder.

The composition of Example 1 of the present invention was concentrated under reduced pressure in a vacuum concentrator, sprayed and dried with a hot air dryer, and the resulting dried product was pulverized to a particle size of 60 mesh with a pulverizer to obtain a dry powder.

The grains, seeds and the composition of Example 1 of the present invention prepared above were prepared by blending in the following proportions.

Grains (30 parts by weight of brown rice, 15 parts by weight of barley, 20 parts by weight of barley),

Seeds (7 parts by weight of perilla, 8 parts by weight of black beans, 7 parts by weight of black sesame),

The composition of Example 1 of the present invention (3 parts by weight),

Reishi (0.5 parts by weight),

Rehmannia (0.5 parts by weight)

As described above in detail a specific part of the present invention, for those of ordinary skill in the art, this specific description is only a preferred embodiment, and it is clear that the scope of the present invention is not limited thereto. Accordingly, the substantial scope of the present invention will be defined by the appended claims and their equivalents.

Claims (6)

As an anti-inflammatory pharmaceutical composition containing yaknan and Jindeukchal extract as an active ingredient,
The yaknan extract is
The fruiting body powder obtained by freeze-drying and pulverizing the yak egg is added to purified water and extracted with hot water,
The hot water extract is filtered under reduced pressure with a filter paper to remove insoluble substances,
Concentrate under reduced pressure using a concentrator equipped with a cooling condenser,
After suspending the concentrated extract under reduced pressure in purified water,
obtained by freeze-drying,
The Jindeukchal extract is
The fruiting body powder obtained by freeze-drying and pulverizing the Jindeukchal was put in purified water and extracted with hot water,
The hot water extract is filtered under reduced pressure with a filter paper to remove insoluble substances,
Concentrate under reduced pressure using a concentrator equipped with a cooling condenser,
After suspending the concentrated extract under reduced pressure in purified water,
It is obtained by freeze-drying,
The yaknan extract and the Jindeukchal extract are mixed in a weight ratio of 1:1, characterized in that
Pharmaceutical composition for anti-inflammatory.
The method of claim 1,
The anti-inflammatory pharmaceutical composition,
An injection of sodium metabisulfite, methylparaben, propylparaben, and sterile distilled water for injection in the anti-inflammatory pharmaceutical composition;
A powder prepared by mixing lactose with the anti-inflammatory pharmaceutical composition and filling an airtight bag;
A tablet prepared by mixing corn starch, lactose and magnesium stearate in the anti-inflammatory pharmaceutical composition, and then tableting;
Capsules prepared by mixing corn starch, lactose and magnesium stearate with the anti-inflammatory pharmaceutical composition and then filling the gelatin capsules;
A pill prepared by mixing lactose, glycerin and xylitol in the anti-inflammatory pharmaceutical composition,
After mixing soybean extract, glucose and starch in the pharmaceutical composition for anti-inflammatory, ethanol is added to dry the granules and then filled in the bag
Anti-inflammatory pharmaceutical composition, characterized in that prepared in any one.
delete delete delete delete